Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 10/20 | 0.40 |
| ▸ | JAK3 | P52333 | 10/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553536 | 0.89 | JAK1 (0.40) | JAK1JAK3JAK2TYK2NPC1 | |
| SCHEMBL31360665 | 0.78 | MEN1 (0.49) | NPC1RAB9ASYKMAPK8ALDH1A1 | |
| SCHEMBL2622287 | 0.78 | MEN1 (0.49) | NPC1RAB9ASYKMAPK8ALDH1A1 | |
| SCHEMBL22585848 | 0.78 | NPC1 (0.40) | NPC1RAB9ASYKAHRALDH1A1 | |
| SCHEMBL22860427 | 0.74 | SYK (0.55) | NPC1RAB9ASYKALDH1A1MAPK1 | |
| SCHEMBL30839178 | 0.74 | ALDH1A1 (0.54) | NPC1RAB9ASYKALDH1A1MAPK1 | |
| SCHEMBL22860689 | 0.74 | ALDH1A1 (0.54) | NPC1RAB9ASYKALDH1A1MAPK1 | |
| SCHEMBL30517140 | 0.74 | JAK3 (0.42) | JAK1JAK3JAK2NPC1RAB9A | |
| SCHEMBL22553618 | 0.72 | SYK (0.46) | NPC1RAB9ASYKAHRALDH1A1 | |
| SCHEMBL22553617 | 0.72 | SYK (0.46) | NPC1RAB9ASYKAHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114007697-A | Antiproliferative agents for the treatment of PAH | 辉瑞公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | JAK1 327/4885JAK3 700/4885JAK2 310/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | JAK1 327/4885JAK3 700/4885JAK2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.